InforMax Announces the Release of GenoMax Version 3.3.Business Editors & Health/Medical Writers BIOWIRE2K BETHESDA, Md.--(BW HealthWire)--Feb. 27, 2002 InforMax, Inc. (Nasdaq:INMX), a leading global provider of life science informatics Same as information technology and information systems. The term is more widely used in Europe. solutions, announced the release of GenoMax(TM) Version 3.3. Released almost two months ahead of schedule, this new version adds over 35 major enhancements and numerous minor updates to the various modules of the GenoMax(TM) enterprise bioinformatics Using computers in biological research to analyze or predict the composition of molecules (nucleic acids, proteins, etc.) and model biologic systems. Bioinformatics is most prominent in the Human Genome Project, which has recorded the three billion chemical base pairs that make up the system. As an integral part of the company's long-term product roadmap, GenoMax(TM) Version 3.3 continues InforMax's unique focus on user needs and emerging scientific research methodologies for its worldwide customer base of academic, biotechnology, and pharmaceutical scientists. Key enhancements to the GenoMax(TM) Gene Expression Analysis Module expand the analysis and visualization Using the computer to convert data into picture form. The most basic visualization is that of turning transaction data and summary information into charts and graphs. Visualization is used in computer-aided design (CAD) to render screen images into 3D models that can be viewed from all capabilities to improve accuracy in mining large gene expression datasets. New automation functions and data management capabilities enable high-throughput workflows and smoothly integrate both sequence and expression data into coordinated research programs in target identification, target validation See validate. validation - The stage in the software life-cycle at the end of the development process where software is evaluated to ensure that it complies with the requirements. and downstream pharmaceutical applications such as predictive toxicology toxicology, study of poisons, or toxins, from the standpoint of detection, isolation, identification, and determination of their effects on the human body. Toxicology may be considered the branch of pharmacology devoted to the study of the poisonous effects of drugs. . GenoMax(TM) Version 3.3 also adds an expanded suite of integrated tools to further enable the efficient management and exploitation of sequence data from multiple genomes, and provides multiple views of those genomes, directly in the context of day to day practical R&D on gene structure and function. "This latest version of our enterprise system highlights InforMax's rapidly evolving and powerful commercial software product development capabilities," said Steve Lincoln, Chief Scientific Officer and Executive Vice President of Product Development at InforMax. "We are focused on developing industry leading solutions for the life science research and development community. Following on our well received launch of GenoMax(TM) Version 3.2 last October, Version 3.3 offers unprecedented levels of performance, usability How easy something is to use. Both software and Web sites can be tested for usability. Considering how difficult applications are to use and Web sites are to navigate, one would wish that more designers took this seriously. See user interface and usability lab. , and supportability, with an increasingly compelling feature-set for the end user." The combined features of this new release address the marketplace's critical need to realize economic benefit from both the Human Genome The human genome is the genome of Homo sapiens, which is composed of 24 distinct pairs of chromosomes (22 autosomal + X + Y) with a total of approximately 3 billion DNA base pairs containing an estimated 20,000–25,000 genes. Project and genomic genomic pertaining to a genome. genomic clone see clone. genomic DNA the DNA sequences making up the genome of an individual. genomic library see gene bank. technologies to improve efficiency and effectiveness in life sciences. Rapidly becoming an industry standard, GenoMax(TM) is an enterprise bioinformatics system that supports High-Throughput Research (TM) (HTR HTR Heater HTR High Temperature Reactor HTR Hard-To-Reach HTR Hunter: the Reckoning (White-Wolf game) HTR Hemolytic Transfusion Reaction (blood transfusion) HTR Hellenic Technology of Robotics ), InforMax's process for minimizing the time and cost of both discovering and validating valuable targets for pharmaceutical, therapeutic, and diagnostic development. This modular family of tools is designed to work with one or more types of genomic and proteomic data, and includes Sequence, Gene Expression, 3D Structure, Protein-Protein Interaction Protein-protein interactions refer to the association of protein molecules and the study of these associations from the perspective of biochemistry, signal transduction and networks. The interactions between proteins are important for many biological functions. and Genome genome: see genetics. genome all the genetic content contained within an organism. An organism's genome is made up of molecules of deoxyribonucleic acid (DNA) that form long strands that are tightly wound into chromosomes, which are found in the Analysis capabilities. Already, InforMax products and services have directly impacted important markets such as cancer biology, infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. research, and agriculture. About InforMax InforMax is the leading global developer of bioinformatics software for High-Throughput Research (TM). Founded in 1990, InforMax products are used by over 1,900 research organizations and more than 31,000 individual scientists worldwide (as of December 31, 2001) to understand and extract value from the massive amounts of data being generated by the Genomic Revolution. Among InforMax's customers are 23 of the top 25 pharmaceutical companies. InforMax's mission is to support the scientific community in drug discovery and to better understand the causes of disease. Our comprehensive portfolio of bioinformatics software solutions help scientists increase the effectiveness and reduce the time and investment it takes to identify and validate biological targets and discover treatments for disease. InforMax bioinformatics software solutions enable a full range of gene-to-genome analysis, interpretation and data mining. Our market-leading products include Vector NTI NTI NewTech Infosystems (software company, Irvine, California) NTI Nuclear Threat Initiative NTI National Transit Institute (New Brunswick, New Jersey) NTI Nunavut Tunngavik Incorporated (R) Suite, the most widely used software suite for enhancing laboratory productivity, and GenoMax(TM), a modular family of analysis programs for integrated analysis of genomic and proteomic data. Additional information about InforMax can be found at our Web site at www.informaxinc.com Statements in this press release that are not strictly historical are "forward-looking" statements, which involve a high degree of risk and uncertainty. Such statements are only predictions, and the actual events or results may differ materially from those projected in such forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. . Factors that could cause or contribute to differences include, but are not limited to, risks associated with InforMax's technologies and the need to keep pace with rapid technological change, the Company's dependence for future revenues on its ability to increase sales of its enterprise platform and successfully establish the GenoMax brand, the Company's dependence on developing and maintaining strategic alliances, development and availability of competitive products or technologies, dependence on patents and the ability to defend the Company's intellectual property rights. These factors and others are more fully described in the Company's annual report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. , as filed with the Securities and Exchange Commission. The Company specifically disclaims any intention or duty to update any forward-looking statements, and these statements represent the Company's current outlook only as of the date given. InforMax, the InforMax logo, Vector NTI, AlignX, BioPlot, and ContigExpress are registered trademarks and GenoMax and High-Throughput Research are trademarks of InforMax, Inc. ProChart is a registered trademark of AxCell Biosciences. All other products or company names are used for identification purposes only, and may be the trademarks of their respective owners. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion